Research Article: Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy
Introduction:
Hepatocellular carcinoma (HCC) is a commonly diagnosed cancer with a high social and economic burden, ranking third in cancer-related global mortality. Because of its insidious onset, approximately % of patients with HCC are diagnosed at intermediate and advanced stages, resulting in a poor prognosis with a -year survival rate of %. –
Read more